
Stanley Druckenmiller's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionaire investor's family office took a fresh position in VKTX during the second quarter, buying roughly 549,000 shares at an average price of $25.33. Fast forward a few months, and those shares are up nearly 36%, with Viking's chart flashing a textbook Golden Cross.
- Track VKTX stock here.